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ABSTRACT
Drug resistant tuberculosis (DR-TB) is challenging particularly in developing countries. As 
such, a previous investigation gave the first insight into the mutational status of the Rifampicin 
Resistance Determining Region (RRDR) of rpoB gene among a restricted number of MTB 
patients’ residents in the Northern Morocco. The purpose of this study was to investigate rpoB 
mutation types and frequencies associated with resistance to Rifampicin in a larger panel of 
MTB patients and to evaluate the usefulness of these mutations to improve the diagnosis of 
resistance to Rifampicin. A panel of 301 consecutive sputum samples belonging to patients 
suscpected of having TB from Northern Morocco was collected at the Pasteur Institute of 
Tangier between 2014-2017. Samples were subjected to conventionel microbiological tests. 
Evaluation of rpoB muational status was assessed by PCR amplification and sequencing of the 
RRDR of the rpoB gene. DST results showed that 26.4% of strains were MDR. Sequencing 
results reported single point mutations in 36 of 65 RIFR isolates of which two had two mutations. 
Aminoacid substitutions in the codon Ser531Leu occurred at the highest frequency (34.46%). 
Overall, 10 aminoacid substitutions have been registered, and the H526S substitution was 
reported for the first time. The present study highlighted that resistance to RIF is a reliable 
marker of MDR-TB, the common mutations successfully detected in the rpoB 531, rpoB526 
and rpoB516 codons provide a foundation for the implementation of molecular approaches 
such as Hain and GeneXpert as a routine tests to detect DR-TB. However, considerable work 
is still necessary to identify extensive mutations associated with DR-TB. 
KEYWORDS: Mycobacterium tuberculosis. Tuberculosis. MDR-TB. XDR-TB. DNA 
sequencing. Drug susceptibility testing. Resistance to Rifampicin. rpoB mutations. Morocco.
INTRODUCTION
Worldwide, tuberculosis (TB) remains a major health problem with nearly 
10 million new cases and 1.5 million deaths yearly, of which more than 95% occur 
in developing countries where drug surveillance and rapid detection of resistance to 
anti-TB drugs are uncommon and the lack of proper health care systems often leads 
to incomplete treatment1. The burden of TB has increased with the emergence and 
dissemination of multidrug-resistant (MDR) and extensively drug-resistant (XDR) 
Mycobacterium tuberculosis (MTB) strains2.
MDR-TB has been defined by the World Health Organization (WHO) as 
resistance to at least rifampicin (RIF) and isoniazid (INH)1, the two most potent 
drugs used for TB treatment. Moreover, it is widely accepted that most RIF resistant 
strains are MDR3. As an example, more than 90% of RIF-resistant isolates are 
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also resistant to INH. Therefore, RIF resistance could be 
considered as a reliable biomarker for MDR-TB detection3.
Previous studies demonstrated that in MTB strains, 
drug resistance is mainly acquired through spontaneous 
mutations, especially single nucleotide polymorphisms 
(SNPs) in specific genes. Upon exposure to anti-TB drugs, 
the resistant populations are selected leading to a sequential 
accumulation of mutations in the respective genes and 
consequently generating MDR-TB cases4. In this context, 
RIF resistance is mainly caused by mutations in an 81-bp 
region of the rpoB gene, named the Rifampicin Resistance 
Determining Region (RRDR) in up to 96% RIF-resistant 
MTB isolates5. In this region, mutations in codons 516, 
526 and 531 prevail in most specimens from different 
populations of different regions and ethnicities3,5-8.
Early detection and genotyping of MTB is of great 
interest to be able to prescribe effective anti-TB therapy, 
to avoid the transmission and to limit the development of 
resistance to one or more drugs9. 
Due to several limitations of traditional techniques, 
novel approaches and molecular tools for rapid and 
reliable detection and identification of MTB have been 
developed and are currently available for TB diagnosis 
and identification of drug resistant TB (DR-TB)10,11. These 
methods include DNA amplification followed by DNA 
sequencing, probe hybridization methods, Restriction 
Fragment Length Polymorphism (RFLP), Single Strand 
Conformation Polymorphism (SSCP), Heteroduplex 
analysis and DNA microarrays12,13.
Of note, PCR amplification followed by DNA 
sequencing is mainly the gold technique and the most widely 
used technique for the identification of mutations in MTB 
specimens8. This technique is the most direct and reliable 
approach for studying genetic mutations allowing the 
identification of both, already known and new mutations that 
are likely to be associated with drug resistance13. Automated 
sequencing has been used by several groups in different 
clinical settings, allowing the detection of the most frequent 
mutations, conferring an excellent benefit for patients’ 
care7,8,13. In Morocco, TB is a major public health concern. 
The global incidence of all clinical forms of tuberculosis is 
very high, with nearly 99 new cases per 100,000 inhabitants 
yearly, corresponding to more than 32,000 new cases per 
year14. According to the last survey on the prevalence of 
MDR-TB strains, resistance was found in 1% of new cases 
and in 11% of patients with a previous TB history1,15.
In Morocco, like in other resource-limited countries, 
WHO guidelines recommend the diagnosis of TB by smear 
microscopy for all new TB cases, and culture associated 
with drug susceptibility testing for retreatment cases1,16. 
Drug susceptibility testing is mainly done by the time 
consuming culture-based proportion method. During the 
last decade, substantial efforts have been made to meet 
the requirement of the Moroccan health-care setting for 
the rapid determination of DR-TB and thereby facilitating 
the early initiation of appropriate anti-TB treatment14. 
Accordingly, many studies on molecular genotyping 
of MTB have been conducted and have allowed the 
introduction of molecular tools in the global management 
of DR-TB in Morocco, namely GenoType MTBDR® (Hain 
Lifescience GmbH, Nehren, Germany) and GeneXpert 
(Cepheid, Sunnyvale, CA, USA)17.
In Tangier, the largest city in Northern Morocco, a 
preliminary study has been conducted to evaluate the 
contribution of GenoType® MTBDRplus assay in TB and 
DR-TB diagnosis and has shown that 75% of RIFR and 
100% of MDR strains harbored mutations in the rpoB gene 
at codons 516, 526 and 53117. Thus, the present study was 
planned to investigate the rpoB mutational status associated 
with resistance to RIF in a large sample to evaluate the 
usefulness of these mutations as molecular biomarkers 
for the rapid detection of DR-MTB strains to improve the 




The study was conducted at the Pasteur Institute of 
Tangier that receives patients from the Tangier region and 
from all Northern Morocco, mainly Larache and Tetouan 
cities. Tangier itself is a hot spot area ranking third with TB 
incidence exceeding 130 cases/100,000 inhabitants17. It is 
also characterized by an important influx of sub-Saharan 
immigrants, who are settled there or waiting for immigration 
to Europe.
Informed consent was obtained from all human adult 
participants and from the parents or legal guardians of 
minors together with the approved consent of the Pasteur 
Institute Ethical Commission (IPM2013-P3).
Sampling and TB diagnosis
A total of 301 sputum samples were recruited from 
January 2014 to February 2017. Samples were collected 
at Tangier’s diagnostic centers, Larache and Tetouan cities 
from patients suspected of TB and sent to the laboratory of 
Mycobacteriology of the Pasteur Institute. The consecutive 
sputum samples were decontaminated by the Petroff method 
and inoculated in Lowenstein–Jensen (L/J) medium18. Direct 
microscopic examination was performed by the Ziehl-Neelsen 
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method19. An aliquot of each decontaminated sample was used 
to extract MTB-DNA for the molecular analysis.
Drug susceptibility testing
All sputum specimens tested were cultured in L/J 
medium. The tubes were examined for bacterial growth after 
28 d of incubation at 37 °C. If no growth or little growth 
was observed, the tubes were left for an extra 14 d.
Drug susceptibility testing (DST) was performed by the 
proportional method with L/J medium20. The critical drug 
concentrations were 0,2 µg/mL for INH and 40 µg/mL for 
RIF. The critical proportion of resistant bacilli necessary to 
define a resistant strain is 1% for the two tested drugs20,21.
DNA extraction by the boiling method
Crude DNA was obtained by scraping a few colonies of 
L/J slants using a sterile disposable loop, then the colonies 
were added to a screw cap microfuge tube containing 
400 µL of distilled water. Each sample was first vortexed 
and then treated by heat shock treatment at 95 °C for 
10 min to inactivate bacteria and release DNA22,23. The 
DNA thermolysate was used immediately in PCR assays 
or stored at -20 °C until further use.
PCR amplification 
In this study, rpoB gene was amplified by PCR using 
the TR8 (5’-TGCACGTCGCGGACCTCCA-3’) and 
the TR9 (5’-TCGCCGCGATCAAGGAGT-3’) primers. 
Amplifications were performed in a total volume of 
50 µL containing 2 µL of template DNA, 0.5 pM/µL of 
each primer, 2.5 mM of each dNTPs (dATP, dCTP, dGTP 
and dTTP), 25 mM MgCl
2
, 1 unit of Hotstar Taq DNA 
polymerase (Qiagen, Hilden, Germany) in 1X Taq DNA 
buffer. Reaction mixtures were first denatured at 94 °C 
for 5 min. Then, thirty-five cycles of amplification were 
performed with denaturation at 94 °C for 1 min, primer 
annealing at 58 °C for 1 min and DNA extension for 1 
min at 72 °C. At the end of the last cycle, the mixtures 
were incubated at 72 °C for 7 min. Positive amplifications 
were confirmed by electrophoresis in 2% agarose gel with 
visualization of the 157 bp band. 
Sequencing analysis
PCR products were purified by the ExoSaP-IT clean up 
system (Thermo Fisher Scientific, Waltham, Massachusetts, 
USA). Sequencing reaction was performed according to 
the manufacturer’s protocol (BigDye Terminator v1.1 
Cycle Sequencing Kit, Applied Biosystems, Thermo 
Fisher Scientific, Waltham, Massachusetts, USA). Direct 
sequencing of amplified PCR products was performed with 
both, the forward (TR8) and the reverse (TR9) primers on 
an ABI PRISM sequencing apparatus (ABI Prism 3130XL 
Genetic Analyser, Applied Biosystems, Thermo Fisher 
Scientific, Waltham, Massachusetts, USA) in the molecular 
and the functional genomics platforms (UATRS-CNRST, 
Rabat, Morocco). Resulting chromatograms were manually 
edited to ensure the sequences accuracy and added to 
the alignment component of the Molecular Evolutionary 
Genetics Analysis5 (MEGA5). The mutations found were 
compared with those included in the TB Drug Resistance 
Mutation Database24.
RESULTS
A total of 301 clinically symptomatic TB patients were 
enrolled in this study, but only 208/301 (69.1%) had positive 
cultures and thus were subjected to the molecular analysis. 
Males represent 79% of the cases vs. 21% of females, 
with a sex ratio of 3.7:1.0. The median children-to-adult 
ratio in this study was 0.04:1.0 (6/149). According to the 
demographic data, the mean age of patients was 38.68 years 
with extreme ages at 12 and 72 years old. The distribution 
of TB cases according to the age showed that TB infection 
prevails in the age group of 26 - 45 years for both, male 
and female TB patients.
Among the 208 patients, 28.37% (59/208) were new 
cases, 14.90% (31/208) relapsed, 7.21% (15/208) failed to 
treatment and 2.88% (6/208) were under treatment after a 
period of abandon. Information regarding 97 cases (46.63%) 
was missing.
Conventional DST was performed on all the 208 strains 
for both, RIF and INH. Among them, 67.3% of the strains 
were pan-susceptible (140/208) and 26.4% were MDR 
(55/208). Mono-resistance to RIF or INH was reported 
in 4.8% (10/208) and 1.4% (3/208) of cases, respectively.
PCR assays of the rpoB gene were successful for all 
RIF-resistant strains (65 cases) which were subjected to 
DNA sequencing and results are reported in Table 1. Single 
point mutations resulting in aminoacid change were found 
in 34 isolates, whereas two isolates had two mutations. 
Nucleotide substitutions in codon 531were the most 
recorded (34.46%). The other hot spot codons, namely 526, 
516 and 513 were mutated in 9.23%, 6.15% and 1.54% of 
the cases, respectively.
Overall, nine substitutions were recorded in RRDR 
of the rpoB gene in 55.4% of TB patients (36/65). Of 
note, two mutations were found in codon 516: D516Y 
(GAC→TAC) and D516V (GAC→GTC), in one and three 
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cases respectively. In codon 531, two mutations were also 
registered: S531W (TCG→TGG) and S531L (TCG→TTG), 
reported in three and twenty two cases, respectively. 
As for codon526, four distinct point mutations were 
reported: H526D(CAC→GAT), H526Y (CAC→TAC), 
H526L (CAC→CTC),  and a new mutation H526S 
(CAC→TCC), found in one, one, three and one case, 
respectively. Only one isolate harbored a mutation in 
codon 513: Q513E (CAA→GAA). Of considerable note, 
29 phenotypically RIFR strains did not harbor any mutation 
in the RRDR of the rpoB gene (44.6%).
DISCUSSION
This study was conducted with samples from different 
cities of Northern Morocco, mainly Tangier, considered 
one of the relevant hot spots of TB in the country. The 
demographic data revealed that TB affects men more than 
women and prevails in adults aged between 26 and 45 years. 
These data are in agreement with previously reported 
studies in Morocco and worldwide1,25,26, suggesting that 
men are likely the main vehicle of TB, therefore, special 
management of male patients will be of great value to 
prevent dissemination of TB to close contacts, especially 
women and children. In this context, the situation would 
be worse with drug resistance to TB. In fact, a number of 
studies reported age and gender as significant risk factors 
for spreading of drug resistant TB27.
In Morocco, as in many countries around the world, 
great efforts have been made for TB diagnosis and 
treatment, and the main challenge is the steady emergence 
of drug resistance and dissemination of drug resistance to 
TB in the population. According to the TB control program 
recommendations, phenotypic DST should be performed for 
retreated cases and patients coinfected with HIV for whom 
the likelihood of acquiring resistance is higher, generating 
MDR and XDR TB28.
It is well known that TB resistance results from 
incomplete treatment, often because of an irregular 
drug supply, inappropriate treatment regimens or poor 
compliance. Multidrug resistance appears to result from 
the stepwise acquisition of mutations in specific genes that 
confer resistance to certain drug targets29. For these reasons, 
considerable efforts have been directed towards ways to 
speed up the process of susceptibility testing, with limited 
costs and minimal complexity. To this end, many molecular 
techniques have been developed and are employed mostly in 
developed countries with a focus on the screening of drug 
resistant-associated mutations13,30.
In Morocco, many studies have already investigated 
the prevalence of first line drug resistance associated with 
genetic mutations in TB patients, mainly from Rabat and 
Casablanca7,8,13,31. Interestingly, Northern Morocco is a very 
particular region, as it is a gateway to Africa, it is marked by 
a migration’s dynamic fueled by both, the native population 
migrant workers and foreigner migration especially of 
sub-Saharan people, generating an upward trend in TB 
incidence. To the best of our knowledge, only one study was 
conducted with samples from Northern Morocco and was 
performed on small sample size to evaluate the contribution 
of GenoType® MTBDRplus assay in DR-TB diagnosis17.
The present study was conducted on 208 TB samples to 
identify the main RIF resistance-related mutations and their 
prevalence. Our findings revealed that 26.4% of strains were 
MDR and were mainly isolated from previously treated 
patients. This prevalence exceeds by far the one previously 
reported by the TB national program (11%) which is very 
alarming15.
In this study, the resistance genotyping was made by 
PCR-sequencing; this gold method was able to identify 
widely known drug resistance-associated mutations, as 
well as novel mutations that could be associated with drug 
resistance. Of particular interest, 55.38% of phenotypically 
RIFR strains harbored mutations in the RRDR, of which 
Table 1 - Frequency of mutations identified by sequencing in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates.
Gene Position Type of mutation Aminoacid changes N° of isolates Frequency (%)
rpoB
513 Substitution of CAA→GAA Glutamine→Glutamic acid 1 1.54







526 Substitution of CAC→GAT 
Substitution of CAC→CTC 


















No Mutation 36 55.4
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94.44% had one single point mutation, whereas the 
remaining 5.56% had two SNPs. These results differ from 
those reported in previous studies conducted in Morocco. 
Indeed, the presence of mutations in the RRDR region of the 
rpoB gene was reported in more than 80% of phenotypically 
RIFR strains7,11,31. This regional variation in the prevalence 
of point mutations in the RRDR has already been reported 
and discussed13,32.
In this study, most mutations found had been already 
reported and are in concordance with previous published 
reports, the most recorded mutation located in the RRDR 
of the rpoB gene being the substitution Ser531Leu6,7,8,31-33.
Overall, mutations in codons 526 and 531 prevail and 
have been widely reported to correlate with high-level 
of resistance and have shown cross-resistance between 
rifabutin and RIF34,35. Mutations in these two sites may 
occur independently without bias, because mutations in 
both codons, 531 (Ser→Leu) and 526 (His→Tyr, His→Asp, 
His→Ser and His→Leu) have a minimal fitness cost in 
comparison with the wild-type susceptible strains5,36.
Of note, mutations in codons 513 and 516, also named 
disputed mutations, result in a low-level of resistance to 
RIF and strains harboring these mutations exhibit high 
sensitivity to rifabutin6,37. Of particular interest, one sample 
harbored a rare Gln513Glu substitution reported once in a 
sample from Taiwan38.
Despite the large number of mutations already reported 
in other studies, the evidence of a new mutation in this 
study, as well as in previous investigations, indicates that 
mutations continue to arise, probably due to the ability of 
MTB to adapt to drug exposure39. However, it remains to be 
verified if this mutation is a functional SNP truly associated 
with RIF resistance in MTB isolates or it is a polymorphism 
than could be useful for phylogenetic investigations.
Among the phenotypically RIFR isolates, 44.62% did 
not carry any mutations in RRDR of the rpoB gene, this 
percentage exceeds by far the data reported worldwide 
(from 1 to 24% vs 44.62% in this study). This might be 
due to (1) the existence of additional mutations outside 
the 81-bp core region of the rpoB gene, (2) mutations in 
alternative subunits of RNA polymerase generating resistant 
phenotypes5,11; (3) mutations in other genes (rpoA and 
rpoC); (4) RIF permeability and (5) some still undefined or 
efflux pumps mechanisms exhibited by these MTB isolates 
leading to RIF-resistance mutations in other genes, which 
ensure the RIF metabolism5,7,8.
Overall, our results corroborate earlier data from 
Morocco regarding the type and frequency of mutations 
in the rpoB gene supporting that rifampicin-resistant 
genotypes harbor, in most cases, mutations in critical 
codons, namely S531L, H526L, D516V.
It is noteworthy that the majority of rpoB gene mutations 
analyzed by direct sequencing in this study correlated well 
with RIF resistance-associated mutations targeted by 
GeneXpert MTB/RIF and Genotype MTBDRplus tests, 
which supports the suitability and accuracy of these tools 
to detect RIF-resistant TB in Morocco. Nevertheless, 
at this stage, the traditional culture and susceptibility 
testing for RIF resistance are not yet to be replaced. Thus, 
there are still many challenges and issues to be solved to 
provide efficient and affordable point-of-care diagnostic 
tests. Nevertheless, the relatively small number of RIF 
resistant samples has limited our ability to draw reliable 
conclusions regarding the frequency and most common 
types of mutations in the RRDR within MTB isolates from 
Northern Morocco. 
CONCLUSION
Molecular assays are accurate and rapid screening tools 
for early detection of DR-TB. The present study focused on 
the detection of novel and already reported mutations in the 
RRDR of the rpoB gene within MTB strains prevalent in 
Northern Morocco. The rapid diagnosis and identification 
of ubiquitous mutations associated with RIF resistance 
in MTB are of great value for the effective treatment and 
monitoring of MDR-TB transmission in Northern Morocco. 
Future studies should focus on sequencing the entire rpoB 
gene as many studies have documented the occurrence 
of common and novel mutations outside the RRDR. In 
addition, novel molecular tests that could identify extensive 
mutations associated with DR-TB beyond the RRDR are 
yet to be developed.
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